# Cadonilimab Plus Nab -Paclitaxel for Patients With Recurrent, or Metastatic Cervical Cancer Resistant to Immune Checkpoint Inhibitors

> **NCT05824494** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Women's Hospital School Of Medicine Zhejiang University** · enrollment: 58 (estimated)

## Conditions studied

- Uterine Cervical Neoplasms
- Cancer of Cervix
- Cervical Cancer
- Cervical Neoplasms
- Uterine Cervical Cancer
- Cancer of the Uterine Cervix

## Interventions

- **DRUG:** Cadonilimab
- **DRUG:** Nab paclitaxel

## Key facts

- **NCT ID:** NCT05824494
- **Lead sponsor:** Women's Hospital School Of Medicine Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2023-06
- **Primary completion:** 2026-06
- **Final completion:** 2026-06
- **Target enrollment:** 58 (ESTIMATED)
- **Last updated:** 2023-05-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05824494

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05824494, "Cadonilimab Plus Nab -Paclitaxel for Patients With Recurrent, or Metastatic Cervical Cancer Resistant to Immune Checkpoint Inhibitors". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT05824494. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*